Add to Calendar 3/27/2019 8:15:00 AM 3/28/2019 2:30:00 PM 2019 Annual Meeting: State of Possible Conference
This year’s Annual Meeting is now the State of Possible Conference where we'll celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate the most pressing challenges facing the life sciences to ensure we can continue this incredible success. Attendees will hear from the brightest minds through keynotes, panel discussions and 15-minute Possible Talks, inspiring and engaging content in the style of a TED Talk. We'll also have a networking reception, the State of Possible Celebration, immediately following Day 1 of the conference, where we'll have great food, drinks, a DJ. Attendees will also have access to the exhibits at the Museum of Science. Join us as we celebrate the State of Possible!
 

If you haven’t attended our Annual Meeting before, it is the premier east coast life sciences conference and this year’s event is better than ever. With speakers like Katrine Bosley, John Maraganore, Jeremy Levin, George Church, and more, we have some of the brightest names in biotech talking about the issues impacting our industry. See our incredible lineup of speakers and topics below. Online registration closes at noon on Tuesday, March 26th. Walk-in registrations will be available on-site. 

Royal Sonesta Boston, 40 Edwin Land Blvd Cambridge MA 02142
Former Founder, President & CEO | X4 Pharmaceuticals
Paula Ragan, Ph.D. is a seasoned leader focused on growing companies and driving innovation with over 25 years of experience in the biotechnology and life sciences industry. She is currently the Managing Director of PMR Advisory LLC, a consulting firm that partners with privately held biotechnology companies to advance their strategic goals. Most recently, Paula founded and served as Chief Executive Officer of X4 Pharmaceuticals, Inc., building the company from inception to a successful initial public offering and advancing its lead asset to FDA approval and U.S. launch as XOLREMDI® (mavorixafor), a first-in-class Breakthrough Therapy for a rare primary immunodeficiency. Before founding X4, Paula served as consulting Chief Business Officer at Lysosomal Therapeutics. Earlier in her career, she spent significant time at Genzyme Corporation, where she held leadership roles in corporate development, manufacturing, and supply chain. Currently, Paula is member of the Board of Advisors for Life Science Cares and a member of the Landmark School Fundraiser Committee. Additionally, Paula serves as a mentor for the Termeer Institute, a non-profit organization cultivating the next generation of biotech leaders. Previously, Paula also served as a Director on the Board of Camp4 Therapeutics. Paula holds a Ph.D. in Medical Engineering and Medical Physics from the Harvard-MIT Division of Health Sciences and Technology (HST), an M.S. in Biomedical Engineering from Boston University, and a B.S. in Mechanical Engineering from Tufts University.

Brought to you by